JNJ

238.68

-0.55%↓

UNH

274.9

-0.55%↓

TMO

546.83

+0.89%↑

ABT

111.08

+0.23%↑

ISRG

492.83

+1.14%↑

JNJ

238.68

-0.55%↓

UNH

274.9

-0.55%↓

TMO

546.83

+0.89%↑

ABT

111.08

+0.23%↑

ISRG

492.83

+1.14%↑

JNJ

238.68

-0.55%↓

UNH

274.9

-0.55%↓

TMO

546.83

+0.89%↑

ABT

111.08

+0.23%↑

ISRG

492.83

+1.14%↑

JNJ

238.68

-0.55%↓

UNH

274.9

-0.55%↓

TMO

546.83

+0.89%↑

ABT

111.08

+0.23%↑

ISRG

492.83

+1.14%↑

JNJ

238.68

-0.55%↓

UNH

274.9

-0.55%↓

TMO

546.83

+0.89%↑

ABT

111.08

+0.23%↑

ISRG

492.83

+1.14%↑

Search

Encompass Health Corp

Slēgts

SektorsVeselības aprūpe

106.24 1.17

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

104.58

Max

108.66

Galvenie mērījumi

By Trading Economics

Ienākumi

-10M

175M

Pārdošana

20M

1.5B

P/E

Sektora vidējais

17.67

84.243

Dividenžu ienesīgums

0.74

Peļņas marža

11.817

Darbinieki

28,851

EBITDA

-14M

333M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt (spēcīgs)

Prognoze 12 mēnešiem

+48.5% upside

Dividendes

By Dow Jones

Dividenžu ienesīgums

Sektora vidējais

0.74%

2.28%

Nākamie ieņēmumi

2026. g. 23. apr.

Nākamais dividenžu datums

2026. g. 14. apr.

Nākamais Ex dividenžu datums

2026. g. 31. marts

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

-3.4B

9.5B

Iepriekšējā atvēršanas cena

105.07

Iepriekšējā slēgšanas cena

106.24

Ziņu noskaņojums

By Acuity

50%

50%

144 / 352 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Weak Bullish Evidence

Encompass Health Corp Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 9. febr. 17:25 UTC

Iegādes, apvienošanās, pārņemšana

Eli Lilly to Buy Biotech Orna Therapeutics for Up to $2.4 Billion -- Update

2026. g. 9. febr. 23:46 UTC

Tirgus saruna

Nikkei May Rise on Hopes for Domestic Policy Measures -- Market Talk

2026. g. 9. febr. 23:43 UTC

Tirgus saruna

Gold Falls on Possible Technical Correction -- Market Talk

2026. g. 9. febr. 23:14 UTC

Tirgus saruna

WiseTech's Bull Reckons AI-Driven Selloff Is Overdone -- Market Talk

2026. g. 9. febr. 22:29 UTC

Tirgus saruna

Australian Coking Coal Price Seen Falling Once Supply Disruptions Ease -- Market Talk

2026. g. 9. febr. 22:19 UTC

Tirgus saruna

Pro Medicus's Business Case Made More Compelling by AI Adoption -- Market Talk

2026. g. 9. febr. 22:08 UTC

Tirgus saruna

Minerals 260 Bull Bets on Production Scale, Takeover Appeal -- Market Talk

2026. g. 9. febr. 22:01 UTC

Peļņas

Friedman Industries Sees 4Q Sales Volume to Generally Consistent With 3Q, With Sequential Improvement in Sales Margins

2026. g. 9. febr. 21:59 UTC

Peļņas

Friedman Industries: Hedging Activities Continued to Perform as Anticipated by Mitigating Impact of Commodity Price Volatility

2026. g. 9. febr. 21:59 UTC

Peļņas

Friedman Industries: Average Selling Prices Began to Improve as Quarter Progressed

2026. g. 9. febr. 21:58 UTC

Peļņas

Friedman Industries 3Q Sales $168M >FRD

2026. g. 9. febr. 21:50 UTC

Tirgus saruna
Iegādes, apvienošanās, pārņemšana

Financial Services Roundup: Market Talk

2026. g. 9. febr. 21:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2026. g. 9. febr. 21:48 UTC

Peļņas

Friedman Industries 3Q EPS 43c >FRD

2026. g. 9. febr. 21:17 UTC

Peļņas

Kyndryl Stock Drops 55%. It's So Much Worse Than an Earnings Miss. -- Barrons.com

2026. g. 9. febr. 21:13 UTC

Tirgus saruna

U.S. Ethanol Crush Margins Near Break-Even -- Market Talk

2026. g. 9. febr. 21:04 UTC

Peļņas

Retail Sales Data Should Confirm a Robust Holiday Season -- Barrons.com

2026. g. 9. febr. 20:30 UTC

Tirgus saruna

Oil Futures Gain As U.S.-Iran Risk Premium Holds -- Market Talk

2026. g. 9. febr. 20:02 UTC

Tirgus saruna

U.S. Natural Gas Falls on Warmer Weather Outlook -- Market Talk

2026. g. 9. febr. 19:42 UTC

Tirgus saruna

Japan's Yield Curve Expected to Flatten -- Market Talk

2026. g. 9. febr. 19:31 UTC

Tirgus saruna

Nike Seen Regaining Relevance With Consumers -- Market Talk

2026. g. 9. febr. 19:27 UTC

Tirgus saruna

Gold Climbs Back Over $5,000/oz -- Market Talk

2026. g. 9. febr. 19:05 UTC

Tirgus saruna

Nike Returns to List of Hottest Brands -- Market Talk

2026. g. 9. febr. 18:19 UTC

Tirgus saruna

Lower Dollar Doesn't Translate to Boost in Grains -- Market Talk

2026. g. 9. febr. 17:41 UTC

Peļņas
Iegādes, apvienošanās, pārņemšana

These Stocks Are Today's Movers: Kyndryl, Hims & Hers, Novo Nordisk, AppLovin, Monday.com, Valaris, and More -- Barrons.com

2026. g. 9. febr. 17:31 UTC

Peļņas
Iegādes, apvienošanās, pārņemšana

These Stocks Are Today's Movers: Kyndryl, Hims & Hers, Novo Nordisk, Monday.com, Valaris, Cleveland-Cliffs, and More -- Barrons.com

2026. g. 9. febr. 17:20 UTC

Tirgus saruna
Iegādes, apvienošanās, pārņemšana

Financial Services Roundup: Market Talk

2026. g. 9. febr. 17:20 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2026. g. 9. febr. 17:17 UTC

Tirgus saruna

Century Aluminum Announces Next Steps of Okla. Project -- Market Talk

2026. g. 9. febr. 17:16 UTC

Peļņas

Kyndryl Stock Drops 56%. It's So Much Worse Than an Earnings Miss. -- Barrons.com

Salīdzinājums

Cenas izmaiņa

Encompass Health Corp Prognoze

Cenas mērķis

By TipRanks

48.5% augšup

Prognoze 12 mēnešiem

Vidējais 156.5 USD  48.5%

Augstākais 160 USD

Zemākais 153 USD

Pamatojoties uz 4 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Encompass Health Corp — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

4 ratings

4

Pirkt

0

Turēt

0

Pārdot

Tehniskais rādītājs

By Trading Central

115.32 / 116.99Atbalsts un pretestība

Īstermiņā

Weak Bullish Evidence

Vidējā termiņā

Strong Bullish Evidence

Ilgtermiņā

Bullish Evidence

Noskaņojums

By Acuity

144 / 352 Rangs Veselības aprūpe

Ziņu noskaņojums

Neutral

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Vidējais

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Encompass Health Corp

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions. It offers services through the Medicare program to federal government, managed care plans and private insurers, state governments, and other patients. The company was formerly known as HealthSouth Corporation and changed its name to Encompass Health Corporation in January 2018. The company was incorporated in 1984 and is based in Birmingham, Alabama.
help-icon Live chat